Lupin launches Prucalopride Tablets in the US market post FDA approval
Lupin begins US sales of Prucalopride Tablets, bioequivalent to Takeda’s Motegrity, for chronic idiopathic constipation treatment
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Sudeep Pharma files DRHP with SEBI for IPO to raise ₹95 Crore
The company files DRHP with SEBI to raise funds via IPO
Bharat Biotech and GSK pledge to lower malaria vaccine price under Gavi replenishment initiative
RTS,S vaccine price to be reduced to below $5 by 2028 through manufacturing scale-up and technology transfer
Lupin receives approval from US FDA for Prucalopride Tablets
The approved tablets are bioequivalent to Takeda’s Motegrity and will be manufactured at Lupin’s Goa facility
Yeztugo holds potential to address key unmet needs for PrEP usage including adherence issues:…
Twice-yearly injectable therapy may improve adherence and expand access to HIV prevention, but affordability and insurance…
Utopia Therapeutics secures $1.5 million seed funding from whale tank to advance obesity vaccine…
Investment will accelerate preclinical development of UT009 and support early-stage trials for novel immunotherapeutic targeting…
Novo Nordisk launches Wegovy for chronic weight management and cardiovascular risk reduction in…
Wegovy, a once-weekly semaglutide injection, is reportedly the first GLP-1 receptor agonist in India approved for both long-term…
CNS innovator oligonucleotide licensing value surges by 339% to $2.8 billion in 2024, reveals…
GlobalData attributes surge in CNS oligonucleotide licensing to increased adoption of ASOs and siRNAs, alongside advancements in…
Rubicon Research acquires Alkem’s Pithampur manufacturing facility for ₹149 crores
The acquisition expands Rubicon’s manufacturing footprint and capabilities in high-potency formulations, supporting its US market…
Glenmark launches TEVIMBRA in India for treatment of advanced lung and oesophageal cancer
Glenmark Pharmaceuticals introduces tislelizumab following CDSCO approval, expanding its oncology portfolio with its first…